Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Assessing liver disease in HIV–HCV coinfected patients

Assessing liver disease in HIV–HCV coinfected patients Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/05/2020 REVIEW URRENT Assessing liver disease in HIV–HCV PINION coinfected patients a b Emmanuel A. Tsochatzis and Laurent Castera Purpose of review It is estimated that up to 10% of patients with HIV have chronic hepatitis C (HCV)–HIV coinfection in the Western world. Assessment of liver disease is essential in such patients in order to diagnose cirrhosis at an early stage, prioritize for anti-HCV treatment but also assess fibrosis regression after sustained viral response (SVR). In this review, we present a critical appraisal of liver disease assessment in patients with HIV–HCV co-infection. Recent findings Liver biopsy has largely been replaced by noninvasive fibrosis assessment in most coinfected patients, although it is still of value if there are concerns of additional diagnoses. Noninvasive assessment includes serum markers and liver stiffness measurement using elastography-based techniques. Certain serum markers, such as FIB-4, SHASTA index, and Fibrometer HIVC have been specifically developed in patients with HIV–HCV coinfection. Transient elastography has advantages over serum markers, as it is not influenced by concomitant antiretroviral medication, HIV replication, CD4 cell count, or nonliver inflammatory processes. Summary Noninvasive markers are increasingly used for clinical decision-making and predicting clinical outcomes in HIV–HCV http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Assessing liver disease in HIV–HCV coinfected patients

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/assessing-liver-disease-in-hiv-hcv-coinfected-patients-yA9zelJ4FN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000176
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/05/2020 REVIEW URRENT Assessing liver disease in HIV–HCV PINION coinfected patients a b Emmanuel A. Tsochatzis and Laurent Castera Purpose of review It is estimated that up to 10% of patients with HIV have chronic hepatitis C (HCV)–HIV coinfection in the Western world. Assessment of liver disease is essential in such patients in order to diagnose cirrhosis at an early stage, prioritize for anti-HCV treatment but also assess fibrosis regression after sustained viral response (SVR). In this review, we present a critical appraisal of liver disease assessment in patients with HIV–HCV co-infection. Recent findings Liver biopsy has largely been replaced by noninvasive fibrosis assessment in most coinfected patients, although it is still of value if there are concerns of additional diagnoses. Noninvasive assessment includes serum markers and liver stiffness measurement using elastography-based techniques. Certain serum markers, such as FIB-4, SHASTA index, and Fibrometer HIVC have been specifically developed in patients with HIV–HCV coinfection. Transient elastography has advantages over serum markers, as it is not influenced by concomitant antiretroviral medication, HIV replication, CD4 cell count, or nonliver inflammatory processes. Summary Noninvasive markers are increasingly used for clinical decision-making and predicting clinical outcomes in HIV–HCV

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.